Skip to main content
Premium Trial:

Request an Annual Quote

BioreclamationIVT Acquires CRO TransCell Science

NEW YORK (GenomeWeb) – Biological specimen provider BioreclamationIVT announced today that it has acquired TransCell Science, a privately held contract research organization specializing in primary cell-based phenotypic screening assays.

"BioreclamationIVT and TransCell Science will form a complete solution spanning biospecimen acquisition to use of those samples within highly relevant in vitro assays," BioreclamationIVT CEO Jeff Gatz said in a statement.

Following the acquisition, TransCell Founder and CEO Chris Hansis will join BioreclamationIVT as CSO. Additional terms of the deal were not disclosed.

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.